Key Players of Cancer Immunotherapy Market and Business Strategies
According to research report the Cancer Immunotherapy Market is projected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0%.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=197577894
Market
growth factors such as increasing adoption of target therapy over
traditional therapy, emergence of biosimilars, increasing demand for
mAbs, high prevalence of cancer. Cancer immunotherapy drugs are designed
to alter or boost the body’s natural immune response to fight cancer
this market is research-driven with a high degree of dependence on the
discovery of molecules that can generate an immune response against
various indications.
The global cancer immunotherapy market is
consolidated in nature, marked with the presence of a few large players.
The prominent players in this market are Amgen (U.S.), AstraZeneca
(U.K.), F. Hoffmann-La Roche Ltd(Switzerland), Bayer AG (Germany),
Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen
Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland),
and Pfizer (U.S.).
Amgen was the largest player in the global
cancer immunotherapy market. The company has a strong presence in the
U.S., Europe, Asia-Pacific, the Middle East, and Africa. In order to
sustain its foothold and further increase its share in the market, the
company pursues the strategy of new product launches, which
significantly impacts the companys customer base.
F. Hoffmann-La
Roche AG accounted for the second-largest share in the cancer
immunotherapy market. The company focuses on developing innovative
products to provide efficient solutions to its customers.
Bristol-Myers
Squibb (BMS) held the third position in the cancer immunotherapy
market. The company has a first-mover advantage as two of its drugs
(Opdivo and Yervoy) have already been approved and commercialized. These
products recently received an approval of oncolytic virus Imlygic and
cancer vaccine Empliciti from the U.S. FDA.
The key strategies
followed by most companies in the cancer immunotherapy market are new
products launches and approvals; expansions; acquisitions; and
partnerships, agreements, and collaborations. The strategy of new
products launches and approvals accounted for the largest share of the
overall growth strategies mapped from 2013 to 2016. Companies seek new
and advanced product approvals to strengthen their product portfolios
and cater to the unmet needs of their customers. Some of the leading
players that adopted this strategy include Amgen (U.S.), F. Hoffmann-La
Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), and Merck (U.S.).
Request Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=197577894
Based
on regions, the global Cancer Immunotherapy market is segmented into
North America, APAC, Europe and the Rest of the World (RoW). North
America is expected to account for the largest share of the market
during the forecast period. Growth in this regional segment is driven by
factors such as increase in patient pool, and initiative taken by the
government for the development of Cancer Immunotherapy.
Comments
Post a Comment